YUKIN THERAPEUTICS

YUKIN THERAPEUTICS is a biotechnology company based in Sophia Antipolis/Biot, France, founded in 2018.

The company focuses on developing cancer therapeutics, particularly small-molecule kinase inhibitors that target the NIK protein. Their research aims to modulate the tumor microenvironment and enhance immune-system infiltration into tumors, with applications in oncology for conditions like melanoma and colorectal cancer. YUKIN THERAPEUTICS is engaged in discovery-stage drug development and optimizing lead candidates for future clinical trials. They have proprietary therapeutic molecules for cancer treatment and have licensed two patents related to their research program. The company is actively working towards identifying its first clinical drug candidate.